Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:OXFD

Oxford Immunotec Global (OXFD) Stock Price, News & Analysis

Oxford Immunotec Global logo

About Oxford Immunotec Global Stock (NASDAQ:OXFD)

Key Stats

Today's Range
$21.99
$21.99
50-Day Range
$21.88
$21.99
52-Week Range
$8.37
$23.11
Volume
N/A
Average Volume
1.10 million shs
Market Capitalization
$570.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States, Europe, Asia, and internationally. The company develops its products using its T-SPOT technology platform that measures marker-specific cellular (T cells) responses at a single cell level and inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. It develops and markets T-SPOT.TB test used to test for tuberculosis; and reagents and methods to purify white blood cells for use in immunology assays. In addition, the company offers T-SPOT.CMV, an immune monitoring test for cytomegalovirus (CMV) for the quantification of effector T cells that respond to stimulation by antigens specific for CMV, as well as for the monitoring of CMV-seropositive responses in transplant recipients at various time-points post-transplantation applications. It serves independent laboratories, hospital systems, and public and private institutions. Oxford Immunotec Global PLC was founded in 2002 and is headquartered in Abingdon, the United Kingdom.

Receive OXFD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oxford Immunotec Global and its competitors with MarketBeat's FREE daily newsletter.

OXFD Stock News Headlines

A Game-Changing Vaccine
Trump won. Buy this coin now.
Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.
Nigeria rolls out new Oxford R21 malaria vaccine
See More Headlines

OXFD Stock Analysis - Frequently Asked Questions

Oxford Immunotec Global PLC (NASDAQ:OXFD) released its quarterly earnings data on Tuesday, November, 3rd. The company reported ($0.01) EPS for the quarter, meeting analysts' consensus estimates of ($0.01). The business earned $19.44 million during the quarter, compared to analysts' expectations of $18.58 million. Oxford Immunotec Global had a negative net margin of 30.51% and a negative trailing twelve-month return on equity of 8.39%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oxford Immunotec Global investors own include Intel (INTC), Gilead Sciences (GILD), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Dynavax Technologies (DVAX), Enterprise Products Partners (EPD) and Gold Resource (GORO).

Company Calendar

Last Earnings
11/03/2020
Today
11/21/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostic Substances
Sub-Industry
N/A
Current Symbol
NASDAQ:OXFD
Fax
N/A
Employees
273
Year Founded
N/A

Profitability

Net Income
$-1,810,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$73.71 million
Cash Flow
$0.02 per share
Book Value
$8.08 per share

Miscellaneous

Free Float
N/A
Market Cap
$570.90 million
Optionable
Not Optionable
Beta
1.42
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

This page (NASDAQ:OXFD) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners